Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis

Zhao,Yuwan; Jing,Zuolei; Li,Yan; Mao,Weifeng

doi:10.3892/or.2016.4785

Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis

Authors:
- Yuwan Zhao
- Zuolei Jing
- Yan Li
- Weifeng Mao
View Affiliations

Affiliations: Department of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, Liaoning 116044, P.R. China, Institute of Gene Engineering Animal Models for Human Diseases, Dalian Medical University, Dalian, Liaoning 116044, P.R. China, Department of Anatomy, College of Basic Medical Sciences, Dalian Medical University, Dalian, Liaoning 116044, P.R. China
Published online on: May 5, 2016 https://doi.org/10.3892/or.2016.4785
Pages: 567-572

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Berberine (BBR) is an isoquinoline alkaloid extracted from medicinal plants such as Hydrastis canadensis, Berberis aristata and Coptis chinensis. BBR displays a number of beneficial roles in the treatment of various types of cancers, yet the precise mechanisms of its action remain unclear. Cisplatin is an effective cancer chemotherapeutic agent and functions by generating DNA damage, promoting DNA damage-induced cell cycle arrest and apoptosis; however, its efficacy is challenged by the resistance of tumor cells in clinical application. The aim of the present study was to investigate the effects of BBR in combination with cisplatin on human breast cancer cells. MTT assay showed that BBR inhibited breast cancer MCF-7 cell growth with a 50% inhibitory concentration (IC50) value of 52.178±1.593 µM and the IC50 value of cisplatin was 49.541±1.618 µM, while in combination with 26 µM BBR, the IC50 value of cisplatin was 5.759±0.76 µM. BBR sensitized the MCF-7 cells to cisplatin in a time- and dose-dependent manner. After treatment of BBR and cisplatin, the cellular pro-apoptotic capase-3 and cleaved capspase-3 and caspase-9 were upregulated and the anti-apoptotic Bcl-2 was downregulated. Importantly, BBR restrained the expression of cellular PCNA, and immunofluoresence analysis of γH2AX showed that BBR increased the DNA damages induced by cisplatin. Taken together, the results demonstrated that BBR sensitized MCF-7 cells to cisplatin through induction of DNA breaks and caspase-3-dependent apoptosis.

View Figures

View References

1	Harris JR, Lippman ME, Veronesi U and Willett W: Breast cancer. N Engl J Med. 327:473–480. 1992. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Jemal A, Grey N, Ferlay J and Forman D: Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
3	Buzdar AU: Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol. 20:993–999. 2009. View Article : Google Scholar : PubMed/NCBI
4	Cohen SM, Mukerji R, Cai S, Damjanov I, Forrest ML and Cohen MS: Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. Am J Surg. 202:646–652; discussion 652–653. 2011. View Article : Google Scholar : PubMed/NCBI
5	Fuertes MA, Castilla J, Alonso C and Pérez JM: Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 10:257–266. 2003. View Article : Google Scholar : PubMed/NCBI
6	Leonard BJ, Eccleston E, Jones D, Todd P and Walpole A: Antileukaemic and nephrotoxic properties of platinum compounds. Nature. 234:43–45. 1971. View Article : Google Scholar : PubMed/NCBI
7	Köberle B, Tomicic MT, Usanova S and Kaina B: Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
8	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
9	Shen DW, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
10	Liu FS: Mechanisms of chemotherapeutic drug resistance in cancer therapy-a quick review. Taiwan J Obstet Gynecol. 48:239–244. 2009. View Article : Google Scholar : PubMed/NCBI
11	Imanshahidi M and Hosseinzadeh H: Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 22:999–1012. 2008. View Article : Google Scholar : PubMed/NCBI
12	Kheir MM, Wang Y, Hua L, Hu J, Li L, Lei F and Du L: Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem Toxicol. 48:1105–1110. 2010. View Article : Google Scholar : PubMed/NCBI
13	Satou T, Akao N, Matsuhashi R, Koike K, Fujita K and Nikaido T: Inhibitory effect of isoquinoline alkaloids on movement of second-stage larvae of Toxocara canis. Biol Pharm Bull. 25:1651–1654. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kuo CL, Chi CW and Liu TY: The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 203:127–137. 2004. View Article : Google Scholar : PubMed/NCBI
15	Chi L, Peng L, Hu X, Pan N and Zhang Y: Berberine combined with atorvastatin downregulates LOX-1 expression through the ET-1 receptor in monocyte/macrophages. Int J Mol Med. 34:283–290. 2014.PubMed/NCBI
16	Zhu Y, Ma N, Li HX, Tian L, Ba YF and Hao B: Berberine induces apoptosis and DNA damage in MG 63 human osteosarcoma cells. Mol Med Rep. 10:1734–1738. 2014.PubMed/NCBI
17	Huang ZH, Zheng HF, Wang WL, Wang Y, Zhong LF, Wu JL and Li QX: Berberine targets epidermal growth factor receptor signaling to suppress prostate cancer proliferation in vitro. Mol Med Rep. 11:2125–2128. 2015.
18	Wu K, Yang Q, Mu Y, Zhou L, Liu Y, Zhou Q and He B: Berberine inhibits the proliferation of colon cancer cells by inactivating Wnt/β-catenin signaling. Int J oncol. 41:292–298. 2012.PubMed/NCBI
19	Ortiz LM, Lombardi P, Tillhon M and Scovassi AI: Berberine, an epiphany against cancer. Molecules. 19:12349–12367. 2014. View Article : Google Scholar : PubMed/NCBI
20	Hwang JM, Kuo HC, Tseng TH, Liu JY and Chu CY: Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Arch Toxicol. 80:62–73. 2006. View Article : Google Scholar
21	Lin CC, Yang JS, Chen JT, Fan S, Yu FS, Yang JL, Lu CC, Kao MC, Huang AC, Lu HF, et al: Berberine induces apoptosis in human HSC-3 oral cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway. Anticancer Res. 27:3371–3378. 2007.PubMed/NCBI
22	Choi MS, Oh JH, Kim SM, Jung HY, Yoo HS, Lee YM, Moon DC, Han SB and Hong JT: Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells. Int J Oncol. 34:1221–1230. 2009.PubMed/NCBI
23	Kim S, Han J, Kim NY, Lee SK, Cho DH, Choi MY, Kim JS, Kim JH, Choe JH, Nam SJ, et al: Effect of berberine on p53 expression by TPA in breast cancer cells. Oncol Rep. 27:210–215. 2012.
24	Kim JB, Yu JH, Ko E, Lee KW, Song AK, Park SY, Shin I, Han W and Noh DY: The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine. 17:436–440. 2010. View Article : Google Scholar
25	Katiyar SK, Meeran SM, Katiyar N and Akhtar S: p53 cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinog. 48:24–37. 2009. View Article : Google Scholar
26	Tan W, Li Y, Chen M and Wang Y: Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomedicine. 6:1773–1777. 2011. View Article : Google Scholar : PubMed/NCBI
27	Kang JX, Liu J, Wang J, He C and Li FP: The extract of Huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-beta and TNF-alpha in human breast cancer cells. Carcinogenesis. 26:1934–1939. 2005. View Article : Google Scholar : PubMed/NCBI
28	Liu J, He C, Zhou K, Wang J and Kang JX: Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cells. Biochem Biophys Res Commun. 378:174–178. 2009. View Article : Google Scholar
29	Tsang CM, Lau EP, Di K, Cheung PY, Hau PM, Ching YP, Wong YC, Cheung AL, Wan TS, Tong Y, et al: Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int J Mol Med. 24:131–138. 2009.PubMed/NCBI
30	Singh T, Vaid M, Katiyar N, Sharma S and Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptors. Carcinogenesis. 32:86–92. 2011. View Article : Google Scholar
31	Krey AK and Hahn FE: Berberine: Complex with DNA. Science. 166:755–757. 1969. View Article : Google Scholar : PubMed/NCBI
32	Peng PL, Kuo WH, Tseng HC and Chou FP: Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int J Radiat Oncol Biol Phys. 70:529–542. 2008. View Article : Google Scholar : PubMed/NCBI
33	Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C, Feng S, Guo H, Xu B, Yang Q, et al: Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS One. 6:e234272011. View Article : Google Scholar : PubMed/NCBI
34	Tong N, Zhang J, Chen Y, Li Z, Luo Y, Zuo H and Zhao X: Berberine sensitizes mutliple human cancer cells to the anticancer effects of doxorubicin in vitro. Oncol Lett. 3:1263–1267. 2012.PubMed/NCBI
35	Guo N, Yan A, Gao X, Chen Y, He X, Hu Z, Mi M, Tang X and Gou X: Berberine sensitizes rapamycin mediated human hepatoma cell death in vitro. Mol Med Rep. 10:3132–3138. 2014.PubMed/NCBI
36	Zhu Q, Chang Y, Yang J and Wei Q: Post-translational modifications of proliferating cell nuclear antigen: a key signal integrator for DNA damage response (Review). Oncol Lett. 7:1363–1369. 2014.PubMed/NCBI